Non-alcoholic Steatohepatitis Biomarkers Market is estimated to be US$ 8177.9 billion by 2029 with a CAGR of 31.3% during the forecast period

Download Sample

Published Date: March 2024

The non-alcoholic steatohepatitis biomarkers market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%

The report "Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

In January 2019, LabCorp. a leading life sciences company, and GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases, announced the signing of a licensing agreement between GENFIT and Covance, LabCorp's drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.
In November 2019, Novartis announced positive interim results from the final part of its phase IIb FLIGHT-FXR adaptive design study, assessing the safety, tolerability, and efficacy of tropifexor in patients with biopsy-confirmed stage 2-3 fibrotic non-alcoholic steatohepatitis (NASH).

Analyst View:

The prevalence rate of non-alcoholic liver diseases has grown significantly. Patients with obesity and type 2 diabetes are projected to be more susceptible to NAFLD and other liver diseases. This is projected to drive the prevalence of non-alcoholic liver diseases. High pollution levels and changes in lifestyle are expected to propel the prevalence of nonalcoholic liver diseases. This, in turn, is anticipated to propel the NASH biomarkers market over the forecast period.

The biopharmaceutical company named “GENFIT” has undertaken an initiative for NASH Education Program in 2016. It’s a public health initiative aimed to create awareness about NASH among patients. These types of programs are measured to expedite utilization of NASH therapeutics. Moreover, GENFIT started Pediatric NAFLD/NASH Program in Europe after approval of elafibranor’s Pediatric Investigation Plan by the European Medicine Agency, which is further expected to ease the drug development program in the future.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Non-alcoholic Steatohepatitis Biomarkers Market”, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029

Key Market Insights from the report:

The non-alcoholic steatohepatitis biomarkers market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%. The market report has been segmented on the basis of type, end-user, and region.

By type, serum biomarkers type segment accounted dominant share as of 2019. Serum biomarkers are the most commonly used diagnostic tools for detection of NASH. Moreover, the introduction of emerging products, such ghrelin & tumor necrosis factor-alpha, asleptin, free fatty acids, apolipoprotein B, apolipoprotein A1, and adiponectin that can provide valuable services complementary to the traditional ones is expected to drive the segment growth.
By end-user, pharmaceutical industry and contract research organizations (CROs) accounted for a dominant share as of 2019. Growing demand for noninvasive NASH diagnostic & monitoring tools by CROs and pharmaceutical manufacturers in the ongoing clinical trials can be attributed to its robust growth. This segment is projected to register a lucrative growth rate in the upcoming years.
By region, North America is expected to account the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years. Driving government initiatives, the presence of sophisticated healthcare amenities, and the growing incidence of diabetes, obesity, and fatty liver disease is supporting the growth of the target market in this region.

Competitive Landscape:

The prominent player operating in the non-alcoholic steatohepatitis biomarkers market includes GENFIT, Gilead, AstraZeneca, Novartis AG, GE Healthcare, EUSA Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, and Pfizer, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period

Key Topics Covered